Associated Papers
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
Clinical relevance of the somatic mutational landscaping in predicting outcome of bladder cancer patients.
Nedjadi T et al.
Scientific Reports, 2025
Mutational Landscape of KIT Proto-Oncogene Coding Sequence in 62 Canine Cutaneous and Subcutaneous Mast Cell Tumors.
Montanucci L et al.
Veterinary Sciences, 2024
Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells.
Sueangoen N et al.
Cancer Immunology, Immunotherapy : Cii, 2024
Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature.
Ręka G et al.
Cells, 2023
Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.
Hasegawa Y et al.
Scientific Reports, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S et al.
Cancers, 2022
Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.
Szpechcinski A et al.
Cancers, 2022
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B et al.
International Journal of Molecular Sciences, 2021
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M et al.
International Journal of Molecular Sciences, 2020
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
de Oliveira Taveira M et al.
Journal of Cancer Research and Clinical Oncology, 2017
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R et al.
Molecular Cancer, 2015
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
Arock M et al.
Leukemia, 2015
Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.
Presneau N et al.
The Journal of Pathology. Clinical Research, 2015
CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival.
Tan WJ et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G et al.
Leukemia Research, 2015
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma.
Jiang N et al.
Oncology Reports, 2014
Anaphylaxis as a clinical manifestation of clonal mast cell disorders.
Matito A et al.
Current Allergy and Asthma Reports, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
A c-kit mutation in exon 18 in familial mastocytosis.
Wöhrl S et al.
The Journal of Investigative Dermatology, 2013
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Verstovsek S
European Journal of Haematology, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN et al.
Plos One, 2013
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Predicting the functional impact of protein mutations: application to cancer genomics.
Reva B et al.
Nucleic Acids Research, 2011
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V et al.
Bmc Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC et al.
International Journal of Laboratory Hematology, 2010
Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.
Rajasekaran R et al.
Amino Acids, 2010
Profiling critical cancer gene mutations in clinical tumor samples.
MacConaill LE et al.
Plos One, 2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
Journal of Cellular and Molecular Medicine, 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009